Navigation Links
Evaluate Launches Enhanced Orphan Drug Intelligence
Date:6/17/2013

tion
  • BENCHMARK current and historical orphan drug deal terms and values
  • IDENTIFY the future value of an orphan drug market via consensus sales forecasts
  • KNOW the latest news and orphan drug designations and approvals
  • For more information on the EvaluatePharma service, please visit http://www.evaluategroup.com.  The complimentary Orphan Drug 2013 report is available for download at http://www.evaluategroup.com/orphandrug2013.

    If you are attending the 2013 DIA Annual Meeting or the EphMRA 2013 conference and would like to meet, please contact us.

    About Evaluate Ltd.

    Established in 1996, Evaluate Ltd. is the leader in high quality life science sector analysis. EvaluatePharma delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance. EvaluateMedTech sets a new standard in integrated analysis and consensus forecasts of the global medical device and diagnostic industry. EvaluateClinical Trials delivers unique intelligence to efficiently and accurately analyze the global clinical trial landscape. A team of more than 85 dedicated healthcare analysts employ rigorous methodologies to collate, organize and deliver the most-up-to-date commercial performance data available. An award-winning editorial team of journalists writing under the EP Vantage name support EvaluatePharma's analysis. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more
    '/>"/>

    SOURCE Evaluate Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation
    2. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
    3. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
    4. Axela Inc. Retains Investment Bank to Evaluate Strategic Opportunities
    5. PathoGenetix and FDA to Evaluate Bacterial Identification System for Use in FDA Public Health and Food Safety Efforts
    6. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
    7. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
    8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
    9. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
    10. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
    11. Neogen Launches Fully Quantitative Lateral Flow Test for DON
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/2/2015)... June 02, 2015 Cirrascale ... blade-based and rackmount computing and storage infrastructure for ... launch of its high density scale-out, two-in-one video ... Slipstream™ RM1622D . The high density, two-in-one system ... product family with Intel® Iris™ Pro graphics P6300 ...
    (Date:6/2/2015)... NEWTOWN, Pa. , June 2, 2015   ... services and technology provider, today announced that David ... has been named Executive Vice President and Chief Financial ... 8, 2015. Peters brings more than 25 ... in pharmaceutical services. "David has extensive and deep knowledge ...
    (Date:6/2/2015)... KONG , June 2, 2015 /PRNewswire/ -- China Cord Blood ... and "our"), China,s leading provider of ... stem cell storage services, today announced that the Special Committee ... appointed Houlihan Lokey ( China ) ... & Hamilton LLP as its United States ...
    (Date:6/2/2015)... 2, 2015 MGB Biopharma ... resistance problem  MGB Biopharma, a biopharmaceutical ... to address the major global problem of antibiotic ... stable intravenous (IV) formulation of MGB-BP-3, designed for the ... The intravenous formulation of MGB-BP-3 is ...
    Breaking Biology Technology:Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3BioClinica Names David Peters New Chief Financial Officer 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3
    ... Schering-Plough Corporation (NYSE: SGP ) today ... in Japan, has received marketing approval for REMERON(R) ... major depressive disorder.(1) The product was developed jointly ... Meiji Seika will market the product under the ...
    ... US Oncology, Inc . today announced that ... pharmacy service, has exceeded the $15 million mark and has assisted ... since the launch of Care Advantage in August 2006. , ... as a positive resource to help so many cancer patients obtain ...
    ... SHANGHAI, July 9 /PRNewswire-Asia/ -- ... of ShangPharma Corporation, today,announces that it has expanded ... first biopharmaceutical company dedicated to the,development of novel ... will provide integrated services in the areas of ...
    Cached Biology Technology:REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients 2REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients 3REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients 4REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients 5OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $15 Million Milestone in Patient Financial Assistance 2OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $15 Million Milestone in Patient Financial Assistance 3OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $15 Million Milestone in Patient Financial Assistance 4Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration 2
    (Date:5/25/2015)... 25, 2015  Australia,s market for wearable technologies is ... saw the advent of several trials and prototypes. The ... is expected to ignite interest in wearables as well ... Australia . This in turn will spur greater ... new partnerships amongst vendors and distributors. ...
    (Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
    (Date:5/18/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
    Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
    ... a species classified as vulnerable and at risk of extinction, ... or more. However, the youngest tortoises are more vulnerable, and ... study by Spanish researchers, who analysed the impact of a ... in Murcia (Spain) on these reptiles. "Tortoises can ...
    ... common form of malignancy in adult Caucasian populations, with more ... alone. Lifestyle risk factors but , ... to the aging structure of Western populations, and as a ... high sun exposure, which is a key risk factor for ...
    ... fisheries could pose a more serious threat to marine ... of Exeter, published today (19 July) in the British ... that tens of thousands of turtles from across the ... fisheries. Focusing on fisheries in Peru, the study ...
    Cached Biology News:Tortoise populations can withstand fires every 30 years 2Some cutaneous HPV types may be involved in non-melanoma skin cancer development 2Study shows small-scale fisheries' impact on marine life 2
    ... provides continuous vertical flow of 99.99% particle-free ... cleanliness standards , Stainless steel ... , Large, ergonomically sloped polycarbonate ... of filling machines or other large process ...
    ... Ideal for biocompatibility testing at ... circulation of air through a clean ... internal temperature up to 140F. Transparent ... strip shields allow easy access to ...
    Ideal for chemical processing that requires downward flow of exhaust fumes. Powderful 1200 CFM blower draws fumes into sub-surface bonded charcoal filter for safe removal of organic vapors (final HEP...
    ... Intracellular Localization Kit provides a straight forward ... of your design, in an efficient yet ... Subcellular localization and functional inhibition of target ... of the labeled siRNA into mammalian cells. ...
    Biology Products: